Immune checkpoint inhibitors and cardiovascular events among patients with cancer: a window into the critical role of the immune system in cardiovascular biology-Reference-Cited by-同舟云学术

Immune checkpoint inhibitors and cardiovascular events among patients with cancer: a window into the critical role of the immune system in cardiovascular biology

Published:2021-10-08 Issue:48 Volume:42 Page:4978-4980
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Kondapalli Lavanya¹^ORCID,Neilan Tomas G²^ORCID

Affiliation:

1. Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

2. Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

https://academic.oup.com/eurheartj/article-pdf/42/48/4978/41849888/ehab708.pdf

Reference17 articles.

1. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs;Haslam;JAMA Netw Open,2020

2. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis;Xu;BMJ,2018

3. Suárez-Almazor ME. Immune-related adverse events of checkpoint inhibitors;Ramos-Casals;Nat Rev Dis Primers,2020

4. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity;Zhang;JACC Cardiooncol,2021

5. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis;Wang;JAMA Oncol,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Arterial inflammation on [18F]FDG PET/CT in melanoma patients treated with and without immune checkpoint inhibitors: CHECK-FLAME I;Atherosclerosis;2024-09

2. The broad spectrum of cardiotoxicities from immunotherapies;Frontiers in Cardiovascular Medicine;2023-09-15

3. Pyroptosis, Metabolism, and Oxidation in Tumorigenesis: Mechanisms and Therapeutic Implications;Antioxidants & Redox Signaling;2023-09-01

4. Heart failure in cardio-oncology and adult congenital heart disease: new challenges and therapeutic targets;European Heart Journal;2022-11-07

5. Which cardiac parameters best predict the cardiovascular outcomes among patients with anti-PD-1 immunotherapy-induced myocardial injury?;Frontiers in Cardiovascular Medicine;2022-09-23